{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-023643","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2025-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.297057+00:00","generated_at":"2026-05-18T00:15:25.149689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M","bullets":["Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.","Gross margin 40% vs 53% prior year; gross profit $0.8M vs $2.6M.","Net loss $2.7M ($1.24/share) vs $2.4M ($1.99/share) in Q2 2024.","Personal Health device sales grew >50% YoY in H1 2025; cash $5.2M at June 30.","Named Bionic P&O as first Ekso Indego Personal distributor; joined NVIDIA Connect program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-023643","json":"https://secwatch.observer/filing/0001437749-25-023643.json","markdown":"https://secwatch.observer/filing/0001437749-25-023643.md","text":"https://secwatch.observer/filing/0001437749-25-023643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000143774925023643/0001437749-25-023643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000143774925023643/ekso20250520_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:15:25.149689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}